Bread Recalled Over 'Glass Fragments' as FDA Warns Consumption Could Cause 'Adverse Health Consequences'
Over 800 cases of Ancient Grains Hoagie Roll, Multigrain Sourdough, and Whole Grain Multigrain sold in six states are affected
Consumers are advised to discard or return recalled products after potential health risks, including injuries to mouth and intestines
Bread and rolls that are sold in six states have been recalled over 'glass fragments.'
In a recall report issued earlier this month, the U.S. Food and Drug Administration (FDA) said three products that are part of Upper Crust Bakery LP were recalled due to 'glass fragment found on top of bread.'
The bread types include Ancient Grains Hoagie Roll, Multigrain Sourdough and Whole Grain Multigrain.
In total, the FDA said 818 cases of the products are suspected of containing glass fragments, including 699 cases of the company's 18-ounce sourdough loaf, which is packaged in corrugated paper cartons and is sold frozen. 89 cases of the hoagie rolls were recalled and 30 of the whole grain multigrain loaf.
The loaves and rolls were sold in Pennsylvania, California, Connecticut, Maryland, Delaware, and Ohio. They appear to be made by Crest Hill Bakery in Maryland.
PEOPLE has reached out to Crest Hill Bakery for comment.
Related: Chocolate Recall Updated to Highest Risk Level, FDA Warns Consumption Could Cause Death
The recall was given a Class 1 recall classification by the FDA. The FDA uses classifications — Class I, II or II — to indicate the 'degree of health hazard' of the recalled product. A Class II recall is defined as 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.'
The agency says that ingesting glass fragments can 'cause injury to the consumer. These injuries may include damage to teeth, laceration of the mouth and throat, or perforation of the intestine.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
Related: Over 400 Ready-to-Eat Products Recalled Due to Possible Listeria Contamination
The Maryland-based bakery first notified the FDA on April 12, per the recall report. The agency added that the recall was voluntary and initiated by the company.
According to Fox Business, the FDA said anyone who purchased the recalled bread and rolls should not eat them and either dispose of them in a secure trash can or return them to where they were purchased for a full refund.
Read the original article on People
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
6 minutes ago
- Yahoo
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
-- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea. The drugmaker's shares climbed 1% in London on the news. The company is looking to new infectious disease products, including its recently launched respiratory syncytial virus vaccine, to offset expected revenue declines from top-selling medicines and looming patent expirations in its HIV portfolio. Gepotidacin is already approved in the U.S. under the brand name Blujepa for treating a common urinary tract infection in women and adolescent girls. The FDA is expected to decide in December on its use for uncomplicated urogenital gonorrhoea, which could offer patients an oral alternative to existing injectable treatments. Separately, GSK and Germany's CureVac last week resolved a long-running patent dispute with Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) over mRNA vaccine technology used during the COVID-19 pandemic. The settlement follows BioNTech's June agreement to acquire CureVac in an all-stock deal worth $1.25 billion to advance work on mRNA-based cancer therapies. Under the settlement, CureVac and GSK will receive $740 million and single-digit percentage royalties on future U.S. sales of COVID-19 vaccines, CureVac said. GSK's share amounts to $370 million, including $50 million to adjust terms from a 2024 licence agreement that expanded their pandemic-era partnership. If BioNTech's takeover of CureVac is completed, related mRNA litigation outside the U.S. will also be resolved, with GSK receiving an additional $130 million and royalties extended to non-U.S. sales. CureVac said the acquisition remains on track under the agreed terms. GSK said it still has separate patent cases against Pfizer and BioNTech in the U.S. and Europe, which are unaffected by this settlement. Related articles GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic USPS blocks major vape distributor over unregulated product shipments - Reuters Exclusive: Opendoor CEO Wheeler breaks silence, EMJ's Eric Jackson calls for more Sign in to access your portfolio


Boston Globe
38 minutes ago
- Boston Globe
Gates Foundation money fills gap in women's health
McKinsey Advertisement That's why the Gates Foundation's announcement of $2.5 billion in investments through 2030 for women's health — Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up The investment will fund research and development in maternal and obstetrical care to make pregnancy and childbirth safer, gynecological care and menstrual health, contraception, nutrition, and treatment of sexually transmitted infections. The Gates Foundation has a history of investing in areas that don't draw market-based or government funding. Its goal is to turn basic scientific research into cost-effective products that can be sold worldwide, particularly in lower-income countries. For example, at the STAT event, foundation founder Bill Gates showed off a plastic drape attached to a container with measuring marks that can be placed on the table where a woman is giving birth and used to measure blood loss. Postpartum hemorrhage can kill birthing women, and Gates said the $1 item can help health care providers identify dangerous blood loss, so treatment can be given sooner. Advertisement On the other end of the technological spectrum, Gates highlighted an artificial intelligence-powered ultrasound, currently being tested by Philips, that can send information to a health worker's cellphone about whether a pregnancy is high-risk. The goal is to make it easier for midwives in areas without ultrasound technicians to take an ultrasound, interpret the results, and send women with high-risk pregnancies for more advanced care. The good news for Massachusetts is the state's strong biotech ecosystem means some ideas funded by the Gates Foundation will be researched and developed here. For example, Giovanni Traverso, director of the Laboratory for Translational Engineering at MIT, received money to develop a transdermal patch that could provide women with long-term contraception. The lab is also developing probiotic medications to treat abnormalities in the vaginal microbiome, a condition associated with risks including painful infection and premature birth. Traverso said the foundation invests in high-risk, early-stage research that few commercial investors will back, then focuses on developing cost-effective products. 'The foundation again and again has been willing to take risks recognizing many things we do don't work. But if a few do, they could have a big impact,' Traverso said. Scott Johnson, CEO of Concord-based Comanche Biopharma, is trying to develop the first drug to treat preeclampsia (high blood pressure during pregnancy). If the drug is approved, Johnson said the Gates Foundation will help distribute it in low-income countries. The foundation gave Comanche Biopharma money to improve the chemical manufacturing process and package the drug in a prefilled syringe, making it cheaper and simpler to deliver. Advertisement Johnson hopes after initial trials in wealthier countries, Gates Foundation funding and expertise will help the company do clinical trials in Ghana, Kenya, and South Africa, with an eye toward getting the drug approved and distributed in areas where sales wouldn't otherwise be economically viable. Other Massachusetts grantees include researchers at Beth Israel Lahey Health, Mass General Brigham, Boston Children's Hospital, Harvard University, Fenway Health, Tufts University, and UMass Chan Medical School. Rasa Izadnegahdar, director of maternal, newborn, child nutrition and health for the Gates Foundation, said the goal is to catalyze private-sector investment in an area of health research with global applicability that has never had sustained funding. 'It's a high return-on-investment area,' Izadnegahdar said. 'That could be economic, societal, or from the lens of survival, including in low- and middle-income country settings. When you invest in improving the life of a woman, you're substantially increasing the opportunity of survival for her children, and it has an impact on the community.' Especially as the federal government cuts support for scientific research, Gates's investment highlights the good that can be done by private philanthropy filling the gap. Editorials represent the views of the Boston Globe Editorial Board. Follow us


Indianapolis Star
4 hours ago
- Indianapolis Star
Sugar cookies sold in 20 states recalled for potential wood contamination: See map
Hundreds of cases of sugar cookies sold at Target are being recalled for potential contamination by a "foreign material," according to a notice posted to the Food and Drug Administration's website. The voluntary recall for the Favorite Day Bakery Frosted Sugar Cookies was issued on July 22 by Give and Go Prepared Foods Corp. in Canada, according to the FDA. Favorite Day is a private label brand sold at Target. In total, 803 cases are being recalled due to the potential foreign contamination. The cookies, which could potentially contain wood, were distributed across 20 different states and Washington, D.C., the notice stated. The recall is classified as a Class II recall, meaning the product "may cause temporary or medically reversible adverse health consequences," according to the FDA. A press release was not issued for the recall, but as of Sunday, Aug. 10, the recall is ongoing. Target did not immediately respond to a request for comment from USA TODAY on Aug. 10. The cookies were sold in the following states and districts: The recalled cookies, Favorite Day Bakery Frosted Sugar Cookies, 10 count, were distributed by Target and produced in Canada. The cookies are a part of Lot 25195, with the UPC number 85239-41250 3. The packs of cookies have varying Best By Dates, as that is determined by when the retailer removed the cookies from the freezers, according to the notice.